Science and Research, Products and Technologies

Phosphoproteomic Strategy for Profiling Osmotic Stress Signaling

Presented here is a phosphoproteomic approach, namely stop and go extraction tip based phosphoproteomic, which provides high-throughput and deep coverage of Arabidopsis phosphoproteome. This approach delineates the overview of osmotic stress signaling in Arabidopsis.

Spotlight

Juno Therapeutics, Inc.

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in clinical trials in refractory leukemia and lymphoma conducted to date.

OTHER VIDEOS

Controlling exothermic reactions with AVA Lab Control Software

video | March 30, 2023

AVA Lab Control Software allows you to automate your chemistry by remotely controlling the devices connected to your jacketed lab reactor with full process data logging....

Watch Now

Processing For Modelling Hydrogen Atoms In Protein Structures

video | March 22, 2023

Neutron Crystallography Data Collection and Processing for Modelling Hydrogen Atoms in Protein Structures....

Watch Now

In-cell Fast Photochemical Oxidation of Proteins

video | March 14, 2023

Characterizing Cellular Proteins with In-cell Fast Photochemical Oxidation of Proteins - a 2 minute Preview of the Experimental Protocol...

Watch Now

Generating Controlled, Dynamic Chemical Landscapes To Study Microbial Behavior

video | March 13, 2023

Generating Controlled, Dynamic Chemical Landscapes to Study Microbial Behavior - a 2 minute Preview of the Experimental Protocol...

Watch Now

Spotlight

Juno Therapeutics, Inc.

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in clinical trials in refractory leukemia and lymphoma conducted to date.

Events